Biomarker
Partnership to advance EEG biomarkers, tech to be used in pending phase 2 MDD study
A biotechnology company has announced a partnership with a precision biomedicine firm to advance the use of electroencephalogram biomarkers across its clinical pipeline in neuropsychiatry and cognition.
EMA approves biomarker study of mitochondrial stimulator for neurodegenerative diseases
The European Medicines Agency has approved enrollment for a phase 1/2a biomarker study to examine a once-daily, oral, brain penetrant mitochondrial stimulator to treat a range of neurological and neuromuscular conditions.
Positive results reported in open label extension of novel ALS therapeutic
A clinical-stage biopharmaceutical company has reported new positive data from a 12-month long-term open label extension of the CNM-Au8 treatment arm in the HEALEY ALS Platform Trial.
Partnership to advance investigational amyloid PET imaging biomarker
A neurotech company has announced an agreement with a radiopharmaceutical firm for the rights to manufacture an investigational imaging biomarker used in PET scans to assess the status of amyloid plaque in the brain.
Speaker: Current biomarkers in asthma care lack stability
ANAHEIM, Calif. — Better biomarkers for diagnosis and prognosis are needed for better personalized asthma care, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
FDA clears blood-based biomarker lab test for traumatic brain injury
The FDA has cleared a traumatic brain injury blood test for commercial availability, paving the way for its distribution to hospitals in the United States.
Positive biomarker data announced in phase 1/2a study of glioblastoma treatment
A Boston-area biopharmaceutical has announced additional positive biomarker data from a phase 1/2a study of a novel cancer vaccine immunotherapeutic intended to treat those with recurrent glioblastoma.
AGA recommends use of fecal calprotectin, serum CRP to inform Crohn’s disease management
Fecal calprotectin and serum C-reactive protein biomarkers can inform disease management for patients with asymptomatic or symptomatic Crohn’s disease, according to an updated clinical practice guideline from the AGA.
Positive interim results announced in phase 2 trial of leukoencephalopathy drug
Vigil Neuroscience Inc. has announced positive interim data from a phase 2 proof-of-concept clinical trial of a monoclonal antibody to treat those suffering from adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.
Octave receives $10M from Michael J. Fox Foundation to advance PD biomarker assay
Octave Bioscience Inc. has received a $10M grant from the Michael J. Fox Foundation for Parkinson’s Research to advance a custom protein biomarker panel to clinically measure Parkinson’s disease activity and progression.